Cutting-Edge AI Driven Transportation Software

Patented Universal Tumor-Targeting Drug Delivery Platform Co. This pharmaceutical company has developed and patented a universal tumor-targeting drug-delivery platform that can improve the safety and efficacy of many existing chemo treatments, with the ability to target numerous different types of cancer. The technology encapsulates existing FDA-approved drugs inside lipid nanoparticles (liposomes or emulsions) coated with patented human-sourced antinuclear antibodies (ANA). The lipid nanoparticle provides long-term storage stability of the drug and controlled release of the drug over time at body-temperature, and is expected to improve the safety and efficacy profile of the drug, including passive accumulation at the tumor while not harming normal tissues. The Company's ANA, sourced from lupus patients, binds to nuclear material present in abundance in areas of necrosis (dead / ruptured cells) present in and around all solid tumors, thus anchoring the drug-filled nanoparticles at the tumor where the nanoparticle is designed to slowly release the drug directly on the tumor for more effect. As the Company's ANA is not tumor-marker specific, but rather targets necrosis present in solid tumors, the technology is designed to "universally" target many different types of cancer including breast cancer, lung, ovarian, colon, prostate, etc., as well as rare childhood cancers. The Company completed a successful proof-of-concept study at Children's Hospital using Ewing's Sarcoma transplanted in immunodeficient mice. Treatment with the Company's forumlation significantly inhibited tumor growth and extended survival times compared to control mice receiving no treatment or treatment with plain liposomal doxorubicin. The Company has been granted Orphan Drug Designation by the FDA on 2 of the lead drug formulations, providing FDA fee waivers, priority review, and 7-years exclusivity upon market approval. The orphan pathway also enables the potential for New Drug Approval after successful completion of Phase 2 studies, with Phase III data collected while in the market, thus significantly lowering the time and cost to market approval. This same drug inside the Company's tumor targeting delivery system will likely have potential to treat other pediatric cancers, and/or cancers in larger adult populations. As the Company's platform and ANA has the potential to improve the safety and efficacy of many existing FDA approved drugs or even compounds in development, the Company anticipates the potential for multiple licensing agreements with multiple pharmaceutical companies seeking to improve their existing portfolio and extend patient life as they advance into clinical stage. And as it may be possible to file for New Drug Approval following successful Phase II studies, the Company anticipates licensing potential at early clinical stage. Multiple exit opportunities exist with high impact & high ROI. The Company is seeking a supportive capital partner to maintain momentum up to $20M. Funding will be used to advance the lead drug through formal Investigational New Drug enabling studies towards New Drug Approval; estimating $3-5 Million now to advance into clinical studies. Preclinical / animal studies estimate ($3 - 5 Million and 12-18 months); follwed by potential combined Phase I-II clinical study in a rare cancer (approximately 2-3 years and $10M) to potential New Drug Approval, plus additional capital to advance additional drugs in the pipeline simultaneously, thus adding tremendous value to the Company's valuation. Valuations of pharma companies often exceed $100 Million valuation at Phase I (approx. 18 months), and New Drug Approval can exceed valuations above $1 Billion. The Company has numerous, improved high-impact cancer drugs advancing with proper support. NDA is required for comprehensive Confidential Information Memorandum crafted by ProNova Partners. Detailed Information Competition: Trying to improve existing therapies and develop novel approaches to hard to treat cancers. Growth & Expansion: Huge market potential. Financing: If the price and deal structure is right. Support & Training: Transition team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

The Company operates in the healthcare technology space with a focus on addressing gaps in dementia and Alzheimer’s care. The company has built an ecosystem where data is collected from caregivers and patients in real-time and pushed into physicians’ EHR/EMR systems to monitor the effectiveness of the prescribed treatment plan. Alzheimer’s Disease and other dementia is the first condition that the platform will be focused on. Its platform supports physicians in managing patients through tools that enable remote monitoring and data collection, allowing for more continuous oversight rather than episodic intervention. The business generates revenue through a combination of public healthcare reimbursements and collaborations with pharmaceutical and research entities. Its model emphasizes integrating digital health solutions into clinical workflows to improve patient tracking and care coordination. The Company’s target users include healthcare providers, caregivers, and researchers working with aging populations impacted by cognitive decline. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Our client developed and operates a multi-market high-demand system capable of identifying criminal subjects in seconds. Access to the cloud-based software is subscription-based with packages ranging from $35,000 to $300,000 annually. The system generates recurring revenue from major retailers. Our client's database is fed with crime and criminal data from over 28,000 sources that update and add new data to their system every day. A global technology agreement was recently signed by a major worldwide electronics manufacturer to integrate our client's system. This significant agreement with the major worldwide electronics manufacturer expands the system from single-enterprise sales to mass-market injection via this new customer's global customer base. The enterprise was designed to bridge the long-standing gap between surveillance video and subject identification and create a next-generation system for subject intelligence. The founder tells us: 'We spent significant time and resources to identify over 28,000 data source points and go through the process to obtain, extract, scrub, and continually update records. Our system and process continued to rapidly develop, allowing further increases in data digestion while completely automating the process. We remain the largest private database of criminals in the world. We developed a multi-market high-demand system capable of identifying criminal subjects in seconds. Whether identifying subjects from surveillance video, home security cameras, video doorbell cameras, or conducting compliance and risk mitigation, our solution and its 70 million+ database is a market-first product with no competition and is used by a variety of Fortune 500 blue-chip customers. The signing of a major worldwide electronics manufacturer to a global technology partnership will add our system to their security products, creating a mass-market injection and significant ARR stream.' With a sales, marketing, and business development team comprised of only 2 people, our client focused initially on penetrating the difficult and highly competitive market of loss prevention within Fortune 500 retailers. After the proprietary system demonstrated a successful track record in identifying subjects and deterring criminal activity, our client gained immediate visibility and has since gained nearly a dozen of the world's largest retailers as clients. Our client has disrupted antiquated identification processes within several of the largest markets, attracting the attention of global manufacturers such as the major worldwide electronics manufacturer's willing to integrate their technology. Our client developed a SaaS system, which provides its '4 I's' Intelligence, Information, Investigation, and Identification. The SaaS is a completed system and is fed with crime and criminal data from over 28,000 sources that update and add new data to the system every day. Access to the cloud-based software is subscription-based with packages ranging from $35,000 to $300,000 annually. Our client's technology has been implemented by many of the largest companies in the world and is currently being integrated by one of the largest technology manufacturers in the world. The strategy is effective, and the reach of the technology is poised to be further expanded. Our client invented and made operational multiple processes and new technology. The system is not only completed and automated, but also proven in the marketplace. One of the achievements worthy of note is that our client's system was responsible for the largest Organized Retail Crime bust in US history. Our client's core competencies and strengths include the highly developed system with ownership of the largest private database of criminal subjects in the world, existing blue-chip customers, a global technology contract with a major worldwide electronics manufacturer, and a technology platform that is extremely valuable in multiple other markets that have not yet been approached. Our client's Intelligence obtains its database data from over 28,000 county, state, federal, and regulatory agency sources. Our client has automated the data digestion process to upload new records, and search/verify changed records several times per day. Once new and or changed data is recognized, an automated process will retrieve the data, categorize, and then implement into our client's system. Our client owns all processes, and websites which they will transfer in full to a buyer. Our client's 'ready to go,' profitable tech, and relationships will enable a buyer to be up and running immediately. NDA is required {LINK ABOVE} to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: N/A Growth & Expansion: See the CIM for details Financing: Offers and investment will be considered Support & Training: As needed specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business. Reason for Selling: To allow the business to rapidly expand world-wide

Our client offers a NFT fantasy franchise sports platform, built on blockchain technology, that introduces true in-game ownership of franchises, teams, and players through the use of NFTs (Non-Fungible Tokens). Unique to our client, customers will own their franchise and their players indefinitely, unless they wish to sell, trade, rent, lease, or perform some other smart contracts. Our client's NFTs are made possible and exceptional by confirming ownership, providing secure transactions, and ensuring that no asset can be duplicated. Our client's product strives to mimic real professional leagues as closely as possible. This innovative platform can be used for all sports around the entire planet! The platform is a fantasy franchise sports game confirms the owner of all assets involved: from franchises to active players; all the way down to the lowest prospect. It also confirms each and every activity. Top 10 Features: 1. Create an account. 2. Once a user has an account, they can either create a fantasy franchise league by paying a fee to receive sports teams and their respective players or receive one by transfer or purchase of a team in an existing league. 3. Any user can stake Sports Coin (SPC) on any real or publicly available fantasy franchise sports game to earn SPC based on the staked players or teams' performance. 4. Players can have one place to see all the relevant stats they need to predict games or follow their favorite players. 5. Free text and soon free audio/video calls. 6. History gives the ENTIRE transaction history. 7. Verify identity using BasisID. 8. Trade, transact, or earn SPC from fantasy franchise NFTs 9. Store Bitcoin/Ethereum to buy Score coin 10. Use the Lightning/Raiden Network for instant free transactions Our client's software is 'ready to go;' and is operating with active customers and net income. NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: N/A Growth & Expansion: Unlimited worldwide. Financing: Sellers will consider, BitCoin preferred Support & Training: As needed specific terms for transition support can be negotiated. The Seller wishes to facilitate a successful and smooth transfer of the Business. Reason for selling: Expansion.

The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A very low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. Existing collaborations with major manufacturers coupled with a current expedited approval process with the FDA presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500k to $1M to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could utlimately yield the balance of funding to fully deploy a commercial version of the technology. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by us. Detailed Information Competition: No current option available besides bed rest. Growth & Expansion: Huge market potential. Support & Training: Full team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

Founded in 2011, the Company is a niche consulting and advisory firm serving in cell therapy, gene and gene-modified cell therapies, other regenerative medicines, tissue engineering, and cell-based drug discovery. The company's core focus is to improve cell & gene therapy innovations by providing consulting services for improving business strategy and achieving major regulatory milestones for companies. The Company has created a one-stop shop for all aspects of cell therapy and gene therapy, including quality checks, regulatory meetings, and submissions with the help of leading experts worldwide. The leadership has a unique combination of experience in the academic, biotech industry, government/FDA, and consulting. They serve biotech, pharma companies, consulting services for healthcare providers, subcontracts for other consulting firms, and contracts with government organizations, which enables them to have 6x+ growth in net income from 2019 2021, i.e., $179,000 to $1,095,000 with the help of 110+ customers served over the past six years. The Company's plan is to consummate a transaction with a supportive growth partner in order to accelerate the company's cell and gene therapy market growth by interacting with industry, academia, government, and other international stakeholders in cell & gene therapies and cell-based drug discovery. NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: Has headquarters in US contractors operate nationwide / portable / buyer can be located worldwide. Competition: A few competitors in the space are in the field but the Company provides best in class services for its respective niche(s). Growth & Expansion: Continually grow and become more profitable with the help of experts that supports preclinical, clinical, and commercial advisory in the manufacturing, regulatory affairs, Quality/GxP, and M&A arenas. Financing: If the price and deal structure is right. Support & Training: Long term transition, Seller wishes to smooth the transition to maximize success with the Company post-closing and spearhead continued growth. Reason for Selling: Growth.

The Company is a diversified business with multiple divisions, but its HVAC/Plumbing division is the cornerstone of operations. This division has built a strong reputation in its regional market by delivering trusted residential services, including plumbing and HVAC system installations, water service and treatment, well pump solutions, and recurring seasonal winterization. Its reputation is reinforced by decades of reliable service to both permanent and seasonal homeowners, positioning the business as the go-to resource in the area. With EPA-certified technicians and dedicated office staff for dispatch and billing, the HVAC/Plumbing division combines technical expertise with responsive customer support, ensuring consistent service quality and long-standing client relationships. In addition, the Company operates hardware, parts, and equipment rental divisions, providing customers with a broad selection of tools, supplies, and repair solutions to complement its core service offerings. NDA is required to receive comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Our client sources an excellent quality bourbon that has a higher yield than a traditional 6-8-year aged bourbon. Due to the higher yield because of less evaporation, they are able to keep the MSRP very competitive and are growing rapidly. They partner with a smaller craft distillery as their co-packer in order to keep production costs down. The founder is a rising, Tennessee-based singer/songwriter with thousands of followers. He uses, and will continue to use, his social media and concerts to publicize the bourbon and allows fans to become partial minority owners of the brand, thus far garnering approximately $200,000 as of the beginning of December 2022. Since the launch of the bourbon brand in 2018 it has earned some of the largest and most prestigious awards which can be awarded in the spirit industry. 1) Named Top 6 in the World in Forbes 2) Featured in Billboard, Rolling Stone, Uproxx, American Songwriter 3) Platinum Los Angeles 4) Double Gold San Francisco (largest award in the world for whiskey to earn) 5) Double Gold New York International 6) Double Gold New York Best Fifty 7) Gold Las Vegas 8) Silver Denver Our client has created a supportive community of real fans who love both the founder's music and the bourbon. Our client has taken the brand as far as 26 states. They will soon expand into Canada and exporting to South Africa & Vietnam is on the horizon. The founder and his partner are willing to stay on the team to bring the Bourbon brand to a much higher national level with a well-capitalized strategic buyer or owner-operator who is passionate about the bourbon industry. An NDA is required to secure a comprehensive Confidential Information Memorandum (CIM). Growth & Expansion: In CIM - NDA Required. Financing: If the price and deal structure is right Support & Training: Provided at no charge to enable a smooth transition Reason for Selling: Other Projects